Myomo Inc. · AMEX:MYO
Myomo — Investor Presentation (November 2024)
25 slides from Myomo's investor presentation, November 2024
Slide 1: Investor Presentation November 2024
INVESTOR PRESENTATION NOVEMBER 2024 Paul R. Gudonis, Chairman and CEO David Henry, CFO Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1
Slide 2: Legal Disclaimer
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and
Slide 3: It's a new world for people suffering from upper extremity impairment
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials It’s a new world for people suffering from upper extremity impairment 3
Slide 4: Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease Stroke TBI Major Dx Other Dx SCI Ø Stroke/CVA Ø Cerebral Palsy Ø Traumatic Brain BPI Ø Multiple Sclerosis Injury PI Ø ALS Ø Sp
Slide 5: Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don't
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t Current Treatment Options Rehabilitation: The Medical Need: ➢ Occupational therapy ➢ Static bracing A lightweight, p
Slide 6: Substantial Market Opportunity
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Substantial Market Opportunity Up to 50,000 We believe the TAM for Up to Senior Insured Population patients 600,000 replenish the the MyoPro approximately patients may prevalence doubles with M
Slide 7: Clarity on Reimbursement
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Clarity on Reimbursement HCPCS Codes L8701, L8702 for MyoPro Ø Issued January 2019 Ø As of January 1, 2024, these codes are in the brace benefit category, meaning lump sum reimbursement Ø Effec
Slide 8: Reimbursement Status: International Markets
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Reimbursement Status: International Markets Germany: Reimbursement for the MyoPro is on a case-by-case basis, with insurance companies often paying for a six-month trial to demonstrate the bene
Slide 9: Recent Clinical Research Accepted for Publication
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Recent Clinical Research Accepted for Publication Myoelectric Arm Orthosis Assists Functional Activities: A 3-Month Home Use Outcome Report Results: Statistically significant and clinically mea
Slide 10: MyoPro Powered Arm Brace: Only Device to Restore Function
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials MyoPro Powered Arm Brace: Only Device to Restore Function ➢ MyoPro uses advanced sensor technology as a brain-computer interface to detect the user’s intention to move via the body’s electromyo
Slide 11: Stroke TBI SCI BPI PI
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Stroke TBI SCI BPI PI https://vimeo.com/1033857664?share=copy 11
Slide 12: Enabling a Paralyzed Arm to Move Again
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Enabling a Paralyzed Arm to Move Again https://vimeo.com/781545268/da823e7df8 https://vimeo.com/781548558/76b59ad742 12
Slide 13: Go-to-Market Approach: How a Patient Obtains a MyoPro
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Go-to-Market Approach: How a Patient Obtains a MyoPro Lead Generation Reimbursement MyoPro Custom Delivery & & Evaluation Approval Fabrication Payment New MyoPro 2+ Remote Measurement Referral
Slide 14: Cost-Effective TV Advertising for Target Demographic
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Cost-Effective TV Advertising for Target Demographic https://vimeo.com/995432363 14
Slide 15: Go-to-Market Approach: Multi-Channel, Emphasis on Direct Billing and International Sales
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Go-to-Market Approach: Multi-Channel, Emphasis on Direct Billing and International Sales Q3 2024 Product Revenue % 4% With Medicare 12% Sales Channels: Reimbursement, we have the 3% opportunity
Slide 16: Nationwide Network of MyoPro Centers of Excellence
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials With Reimbursement in Place, We Intend to Develop a Nationwide Network of MyoPro Centers of Excellence (COE’s) O&P Clinics (COE’s) Payers • Medicare-Accredited Partners $ • In-Network with Paye
Slide 17: International Update: Activity in Key Markets
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials International Update: Activity in Key Markets New Rep added in UK Japan Patent Issued China JV company established - 19.9% Equity Interest for MYO shareholders China patents issued Launch of JV
Slide 18: Backlog and Pipeline are Leading Indicators of Revenue
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Backlog and Pipeline are Leading Indicators of Revenue Backlog 1400 Pipeline 1200 350 316 282 1000 300 275 1263 250 230 800 200 154 164 600 150 1046 131 100 400 53 50 200 0 2019 2020 2021 2022
Slide 19: Strong Revenue Growth Continued in Third Quarter
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Strong Revenue Growth Continued in Third Quarter Quarterly Product Revenue 12,000,000 Midpoint of Guidance 10,000,000 8,000,000 6,000,000 4,000,000 2,000,000 0 1Q 2Q 3Q 4Q 2019 2020 2021 2022 2
Slide 20: P&L and Key Balance Sheet Metrics
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials P&L and Key Balance Sheet Metrics P&L Key Balance Sheet Metrics Actual Actual Actual Actual ($000's) Q3'24 Q3'23 2023 2022 Actual Actual ($000's) Q3'24 Q2'24 Product Revenue $ 9,208 $ 5,030 $ 1
Slide 21: Key Milestones Driving Revenue Growth
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Key Milestones Driving Revenue Growth Revenues Medicare $M Part B China JV revenues license 30-31 revenue, Increased full Record year revenue Record Int’l Int’l guidance. Expanded # and VA reve
Slide 22: Capital Requirements and Cash Flow Breakeven
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Capital Requirements and Cash Flow Breakeven It is achievable to be cash flow breakeven and approach Adjusted EBITDA breakeven in the fourth quarter of 2024. Requirements: Ø No unforeseen suppl
Slide 23: Strategic Plan to Achieve Revenue Growth
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Strategic Plan to Achieve Revenue Growth nel Increased Marketing, New International h an P C Markets, Medicare Reimbursement, O& and New Product Introduction for e lop a re v ic De M ed ket Con
Slide 24: Leadership Team & Board of Directors
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Leadership Team & Board of Directors Management Team Members Board of Directors Paul R. Gudonis Barry Camrell Thomas Kirk Chairman & CEO VP of QA/RA Lead Independent Director Scaled multiple te
Slide 25: Thank You! For Additional Information
Thank You! For Additional Information: Paul R. Gudonis, CEO David Henry, CFO paul@myomo.com david.henry@myomo.com 617-401-2623 508-344-5235 25